Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence^®(1) (denosumab-bnht) and Bomyntra^®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia^®(3) (denosumab) and Xgeva^®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence^®(1)  and Bomyntra^®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia^®(3) and Xgeva^®(4) are registered trademarks of Amgen Inc.

Read the full press release here.